# Molecular Partners:

## Building Tomorrow's Breakthroughs

***Molecular Partners AG, Switzerland (SIX: MOLN)***

*February 26, 2020*

*9th Annual SVB Leerink Global Healthcare Conference*

MOLECULAR partners

# Disclaimer

This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG’s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit.

# Molecular Partners in Brief



## Strengthened Team, Solid Funding

- ✓ **Nicolas Leupin** joined as **CMO** from Argenx
- ✓ **Newly nominated board members:**
  - Sandip Kapadia, CFO Intercept Rx
  - Michael Vasconcellas, CMO Flatiron Health
  - Vito Palombella, CSO Surface Oncology
- ✓ Well financed through mid-2021, **on-track towards recurring income** with expected abicipar launch in 2020 by Allergan



## Burgeoning Oncology Pipeline

- ✓ **MP0250** focused on MM with unique activity in patients that did not benefit from other treatments
- ✓ **MP0310 (AMG 506)**: Collaboration with Amgen to co-develop MP0310 & first patient cohort dosed in Phase 1 trial
- ✓ New development candidate, **MP0317 (FAPxCD40), added to pipeline**
- ✓ First DARPin® candidates binding **peptide-MHC** passed specificity threshold

## Progress Towards Approval

- ✓ **BLA** of **abicipar accepted** by FDA, MAA of abicipar validated by EMA
- ✓ **90% of patients** show vision gains which were maintained in the 2nd year with **q12 dosing** of abicipar
- ✓ MAPLE data supports optimized manufacturing process for **improved tolerability**



MOLECULAR partners

# Differentiated Products by Therapeutic Design









## DARPin® Features

**Rigid-body target binding**



DARPin® domain

**Multi-DARPin® formatting**

- Small size: 15 kDa
- Simple repetitive architecture: 1 polypeptide
- High affinity and specificity
- Tunable half-life






MOLECULAR partners

# DARPin® Platform: A Validated Source for Drug Candidates

- **Abicipar: Ophthalmic validation**
  - Demonstrated safety and activity in >1,500 patients
  - Manufacturing at commercial scale established
  - Regulatory applications accepted by FDA and EMA
- **MP0250: Systemic validation**
  - Long half-life (HSA DARPin binder, 12 day half-life)
  - Low immunogenicity
  - Proof of multi-DARPin® potential to engage with multiple targets simultaneously
- **Novel Therapeutic Designs (NTD) applied**
  - Phase 1 enrolling for MP0310 (AMG 506)

# Flexible Business Model to Maximize Product Value

- Investment in **proprietary pipeline** to bring DARPin® candidates forward

- Engage in **collaborations** to maximize product candidate value
  - **Academic & industry collaborations** to access biology capabilities
  - **Allergan** is advancing abicipar in ophthalmology
  - Collaboration with **Amgen** to co-develop MP0310




- **Cross-funding** of pipeline via partnered assets
  - AGN: USD 360m in potential MS & DD royalties to mid-teens
  - AMG: USD 50m upfront payment, USD 497m in potential MS & DD royalties to high-teens



MOLECULAR partners

# A Balanced and Robust Portfolio



# Abicipar on Track for Market Launch in 2020

- Primary and secondary endpoints of Phase 3 trials support abicipar potential to become the first fixed 12-week anti VEGF in nAMD
  - Reduce patient burden from injections and allow for less doctor visits
  - Potential to translate visual acuity gains as seen in clinical trials into the real world setting
- **FDA has accepted BLA** for abicipar; US launch, following FDA review, expected mid-2020
- **EMA has validated MAA** for abicipar**,** corresponding EMA decision possible by H2 2020
- Data from MAPLE trial outline pathway for ongoing optimization of manufacturing process and continued reduction of intraocular inflammation
  - Severe inflammation down to 1.6% (vs. 3.5%); no cases of endophthalmitis or retinal vasculitis
- Allergan plans to start DME trial in 2020, based on material produced with modified manufacturing process

# Phase 3 Efficacy Results (SEQUOIA study, 1yr data)




Primary Endpoint: STABLE VISION Abicipar Q8 and Q12 Non-Inferior to Ranibizumab Q4




Secondary Endpoint: Change in BCVA From Baseline Abicipar Q8 and Q12 in SEQUOIA Non-Inferior to Ranibizumab




Secondary Endpoint: Change in CRT similar across in all groups

- Source: Allergan July, 2018 and October 2018



MOLECULAR partners

# Secondary Endpoint: Mean Change in CRT From Baseline at Weeks 52 and 104

*Phase III CEDAR & SEQUOIA*




**CRT improvement after initial doses were maintained to Week 104 with quarterly abicipar injections (10) vs. monthly ranibizumab injections (25)**

CRT = central retinal thickness

***Abicipar is under investigation and the safety and efficacy of this product have not been established.***

1. Khurana RN, et al. Presented at AAO 2019 Annual Meeting in San Francisco, CA, USA; Oct 12-15, 2019.

MOLECULAR partners

# Intraocular Inflammation Through Weeks 52[1] and 104[2] Comparable Risk to ranibizumab in Year 2




- Abicipar had comparable risk of IOI to ranibizumab in Year 2
- There were no new cases of retinal vasculitis and endophthalmitis from abicipar groups in Year 2

***Abicipar is under investigation and the safety and efficacy of this product have not been established.***


Khurana RN, et al. Presented at AAO 2018 Annual Meeting in Chicago, IL, USA; Oct 27-30, 2018
Khurana RN, et al. Presented at AAO 2019 Annual Meeting in San Francisco, CA, USA; Oct 12-15, 2019




MOLECULAR partners

# Intraocular Inflammation (IOI) by Maximum Severity




Severity was reported according to investigator assessment

# Conclusions

**Abicipar produced through a modified manufacturing process demonstrated an improved safety profile compared with the phase 3 studies**

- The overall incidence of intraocular inflammation (IOI; BL to Week 28)
  - MAPLE study = 8.9% (Q8)
  - CEDAR+SEQUOIA phase 3 studies = 13.1% (Q8) and 13.8% (Q12)
- Most IOI events were assessed as mild to moderate in severity and occurred within the first 4 injections of abicipar
- There were no reported cases of endophthalmitis or retinal vasculitis in the MAPLE study
- Visual acuity (VA) in the majority of patients with IOIs in the MAPLE study recovered to baseline levels or better by the last visit
  - 2 patients in MAPLE lost 4–5 letters; all others had stable or improved VA
  - All but 3 patients had VA 20/40 or better after resolution of IOI

# Expected 2020 Catalysts

| | 2020 |
|---|---|
| **Abicipar** | ▪ Approval and launch in nAMD (US and EU)<br>▪ Initiation of Abicipar Phase 3 in DME patients |
| **MP0250** | ▪ Additional P2 data from PI-combo trial<br>▪ Continued development of MP0250 in partnership |
| **MP0274** | ▪ Establish dose and define path forward |
| **MP0310** | ▪ Identify MP0310 dose in ongoing phase 1<br>▪ Initiation MP0310 combination trials |
| **Research** | ▪ Prepare for MP0317 IND submission<br>▪ Selection of 1st pMHC candidate for development<br>▪ Multiple updates at AACR & other international conferences |

Funding into H2 2021 (excl. any future proceeds related to Abicipar and partnerships)



MOLECULAR partners

# Thank You!

MOLECULAR partners

Molecular Partners AG
Wagistrasse 14
8952 Zürich-Schlieren
Switzerland
www.molecularpartners.com
T +41 44 755 77 00

**IR Agenda**

| | |
|---|---|
| March 20, 2020 | Expected Publication of Annual Report 2019 |
| April 29, 2020 | Annual General Meeting |